Bibliografía científicaBibliografía científica

En esta sección encontrará una selección de las publicaciones científicas sobre los Trastornos del Movimiento para los 11 diferentes tipos establecidos por la International Parkinson & Movement Disorder Society. Se han seleccionado sólo aquellas publicaciones que presenten el término de búsqueda en el título (inglés).

Los artículos presentados incluyen aquellos publicados desde enero de 2010. El listado de publicaciones de actualizará mensualmente. Si lo desea, puede recibir una alerta de la actualización por correo electrónico. Para ello ha de registrarse.

Búsqueda
Enfermedad de Parkinson y Parkinsonismo Parkinson’s disease & Parkinsonism 753 artículos Viendo del 1 al 40 de 753 artículos
Pub MED

Depressive symptoms in Parkinson's disease are related to decreased left hippocampal volume: correlation with the 15-item shortened version of the Geriatric Depression Scale.NUEVO

Goto M, Kamagata K, Hatano T, Hattori N, Abe O, Aoki S, Hori M, Gomi T.
Acta Radiol. 2018 Mar;59(3):341-345. doi: 10.1177/0284185117719100. Epub 2017 Jul 10.
Pub MED

Word selection processing in Parkinson's disease: When nouns are more difficult than verbs.NUEVO

Silveri MC, Traficante D, Lo Monaco MR, Iori L, Sarchioni F, Burani C.
Cortex. 2018 Mar;100:8-20. doi: 10.1016/j.cortex.2017.05.023. Epub 2017 Jun 7.
Pub MED

α-Synuclein nonhuman primate models of Parkinson's disease.NUEVO

Marmion DJ, Kordower JH.
J Neural Transm (Vienna). 2018 Mar;125(3):385-400. doi: 10.1007/s00702-017-1720-0. Epub 2017 Apr 22. Review.
Pub MED

Updates on immunity and inflammation in Parkinson disease pathology.NUEVO

Joshi N, Singh S.
J Neurosci Res. 2018 Mar;96(3):379-390. doi: 10.1002/jnr.24185. Epub 2017 Oct 26. Review.
Pub MED

Production of verbs related to body movement in amyotrophic lateral sclerosis (ALS) and Parkinson's Disease (PD).NUEVO

Cousins KAQ, Ash S, Grossman M.
Cortex. 2018 Mar;100:127-139. doi: 10.1016/j.cortex.2017.08.030. Epub 2017 Sep 8.
Pub MED

Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.NUEVO

Masilamoni GJ, Smith Y.
J Neural Transm (Vienna). 2018 Mar;125(3):337-363. doi: 10.1007/s00702-017-1774-z. Epub 2017 Aug 31. Review.
Pub MED

Parkinson's disease compromises the appraisal of action meanings evoked by naturalistic texts.NUEVO

García AM, Bocanegra Y, Herrera E, Moreno L, Carmona J, Baena A, Lopera F, Pineda D, Melloni M, Legaz A, Muñoz E, Sedeño L, Baez S, Ibáñez A.
Cortex. 2018 Mar;100:111-126. doi: 10.1016/j.cortex.2017.07.003. Epub 2017 Jul 17.
Pub MED

Alteration of autophagy-related proteins in peripheral blood mononuclear cells of patients with Parkinson's disease.NUEVO

Miki Y, Shimoyama S, Kon T, Ueno T, Hayakari R, Tanji K, Matsumiya T, Tsushima E, Mori F, Wakabayashi K, Tomiyama M.
Neurobiol Aging. 2018 Mar;63:33-43. doi: 10.1016/j.neurobiolaging.2017.11.006. Epub 2017 Nov 21.
Pub MED

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.NUEVO

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.
Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.
Pub MED

Trunk Exercises Improve Gait Symmetry in Parkinson Disease: A Blind Phase II Randomized Controlled Trial.NUEVO

Hubble RP, Naughton G, Silburn PA, Cole MH.
Am J Phys Med Rehabil. 2018 Mar;97(3):151-159. doi: 10.1097/PHM.0000000000000858.
Pub MED

A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy.NUEVO

Colamartino M, Duranti G, Ceci R, Sabatini S, Testa A, Cozzi R.
Toxicol In Vitro. 2018 Mar;47:1-7. doi: 10.1016/j.tiv.2017.10.020. Epub 2017 Oct 26.
Pub MED

Hoehn and Yahr staging of Parkinson's disease in relation to neuropsychological measures.NUEVO

Modestino EJ, Reinhofer A, Blum K, Amenechi C, O'Toole P.
Front Biosci (Landmark Ed). 2018 Mar 1;23:1370-1379.
Pub MED

200 Years of Parkinson's disease: what have we learnt from James Parkinson?NUEVO

McDonald C, Gordon G, Hand A, Walker RW, Fisher JM.
Age Ageing. 2018 Mar 1;47(2):209-214. doi: 10.1093/ageing/afx196.
Pub MED

Parkinson's disease-linked DNAJC13 mutation aggravates alpha-synuclein-induced neurotoxicity through perturbation of endosomal trafficking.NUEVO

Yoshida S, Hasegawa T, Suzuki M, Sugeno N, Kobayashi J, Ueyama M, Fukuda M, Ido-Fujibayashi A, Sekiguchi K, Ezura M, Kikuchi A, Baba T, Takeda A, Mochizuki H, Nagai Y, Aoki M.
Hum Mol Genet. 2018 Mar 1;27(5):823-836. doi: 10.1093/hmg/ddy003.
Pub MED

Nuclear translocation of DJ-1 protects adult neuronal stem cells in an MPTP mouse model of Parkinson's disease.NUEVO

Sun Y, Wang Y, Zhao X, Pu X.
Neuroreport. 2018 Mar 7;29(4):301-307. doi: 10.1097/WNR.0000000000000956.
Pub MED

Reward processing dysfunction in ventral striatum and orbitofrontal cortex in Parkinson's disease.NUEVO

du Plessis S, Bossert M, Vink M, van den Heuvel L, Bardien S, Emsley R, Buckle C, Seedat S, Carr J.
Parkinsonism Relat Disord. 2018 Mar;48:82-88. doi: 10.1016/j.parkreldis.2017.12.024. Epub 2017 Dec 24.
Pub MED

The association between objectively measured physical activity, depression, cognition, and health-related quality of life in Parkinson's disease.NUEVO

van Uem JMT, Cerff B, Kampmeyer M, Prinzen J, Zuidema M, Hobert MA, Gräber S, Berg D, Maetzler W, Liepelt-Scarfone I.
Parkinsonism Relat Disord. 2018 Mar;48:74-81. doi: 10.1016/j.parkreldis.2017.12.023. Epub 2017 Dec 23.
Pub MED

Poor nighttime sleep is positively associated with dyskinesia in Parkinson's disease patients.NUEVO

Mao CJ, Yang YP, Chen JP, Wang F, Chen J, Zhang JR, Zhang HJ, Zhuang S, Xiong YT, Gu CC, Yuan W, Huang JY, Fay A, Zhong CK, Liu CF.
Parkinsonism Relat Disord. 2018 Mar;48:68-73. doi: 10.1016/j.parkreldis.2017.12.022. Epub 2017 Dec 21.
Pub MED

The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson's disease.NUEVO

Malec-Litwinowicz M, Plewka A, Plewka D, Bogunia E, Morek M, Szczudlik A, Szubiga M, Rudzińska-Bar M.
Neurol Neurochir Pol. 2018 Mar;52(2):243-251. doi: 10.1016/j.pjnns.2017.11.009. Epub 2017 Nov 21.
Pub MED

The daily lives of people with Parkinson's disease.NUEVO

Valcarenghi RV, Alvarez AM, Santos SSC, Siewert JS, Nunes SFL, Tomasi AVR.
Rev Bras Enferm. 2018 Mar-Apr;71(2):272-279. doi: 10.1590/0034-7167-2016-0577. English, Portuguese.
Pub MED

Increased serum levels of TNF-α and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity.NUEVO

Kouchaki E, Kakhaki RD, Tamtaji OR, Dadgostar E, Behnam M, Nikoueinejad H, Akbari H.
Clin Neurol Neurosurg. 2018 Mar;166:76-79. doi: 10.1016/j.clineuro.2018.01.022.
Pub MED

Do subjects with minimal motor features have prodromal Parkinson disease?NUEVO

Chu Y, Buchman AS, Olanow CW, Kordower JH.
Ann Neurol. 2018 Mar;83(3):562-574. doi: 10.1002/ana.25179. Epub 2018 Mar 10.
Pub MED

The launch of opicapone for Parkinson's disease: negatives versus positives.NUEVO

Castro Caldas A, Teodoro T, Ferreira JJ.
Expert Opin Drug Saf. 2018 Mar;17(3):331-337. doi: 10.1080/14740338.2018.1433659. Review.
Pub MED

Optical coherence tomography findings in Parkinson's disease.NUEVO

Aydin TS, Umit D, Nur OM, Fatih U, Asena K, Nefise OY, Serpil Y.
Kaohsiung J Med Sci. 2018 Mar;34(3):166-171. doi: 10.1016/j.kjms.2017.11.006. Epub 2017 Dec 6.
Pub MED

Vulnerability of glia and vessels of rat substantia nigra in rotenone Parkinson model.NUEVO

Elgayar SAM, Abdel-Hafez AAM, Gomaa AMS, Elsherif R.
Ultrastruct Pathol. 2018 Mar-Apr;42(2):181-192. doi: 10.1080/01913123.2017.1422066.
Pub MED

Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.NUEVO

Lhommée E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, Timmermann L, Hälbig TD, Pineau F, Durif F, Witjas T, Pinsker M, Mehdorn M, Sixel-Döring F, Kupsch A, Krüger R, Elben S, Chabardès S, Thobois S, Brefel-Courbon C, Ory-Magne F, Regis JM, et al.
Lancet Neurol. 2018 Mar;17(3):223-231. doi: 10.1016/S1474-4422(18)30035-8.
Pub MED

DBS for Parkinson's disease with behavioural disturbances.NUEVO

Antonini A, Obeso JA.
Lancet Neurol. 2018 Mar;17(3):195-197. doi: 10.1016/S1474-4422(18)30044-9. No abstract available.
Pub MED

Hyperbaric oxygen treatment for Parkinson's disease with severe depression and anxiety: A case report.NUEVO

Xu JJ, Yang ST, Sha Y, Ge YY, Wang JM.
Medicine (Baltimore). 2018 Mar;97(9):e0029. doi: 10.1097/MD.0000000000010029.
Pub MED

Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease.NUEVO

Song W, Kothari V, Velly AM, Cressatti M, Liberman A, Gornitsky M, Schipper HM.
Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27328. [Epub ahead of print]
Pub MED

Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.NUEVO

Goldman JG, Holden SK, Litvan I, McKeith I, Stebbins GT, Taylor JP.
Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27323. [Epub ahead of print] Review.
Pub MED

Animal models of l-dopa-induced dyskinesia in Parkinson's disease.NUEVO

Cenci MA, Crossman AR.
Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27337. [Epub ahead of print] Review.
Pub MED

Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease.NUEVO

Grassi D, Howard S, Zhou M, Diaz-Perez N, Urban NT, Guerrero-Given D, Kamasawa N, Volpicelli-Daley LA, LoGrasso P, Lasmézas CI.
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2634-E2643. doi: 10.1073/pnas.1713849115. Epub 2018 Feb 27.
Pub MED

Parkinson's Disease: Patients' Knowledge, Attitudes, and Interest in Genetic Counseling.NUEVO

Maloney KA, Alaeddin DS, von Coelln R, Dixon S, Shulman LM, Schrader K, Guan Y.
J Genet Couns. 2018 Mar 2. doi: 10.1007/s10897-018-0239-3. [Epub ahead of print]
Pub MED

Single-Cell RNA-Seq of Mouse Dopaminergic Neurons Informs Candidate Gene Selection for Sporadic Parkinson Disease.NUEVO

Hook PW, McClymont SA, Cannon GH, Law WD, Morton AJ, Goff LA, McCallion AS.
Am J Hum Genet. 2018 Mar 1;102(3):427-446. doi: 10.1016/j.ajhg.2018.02.001.
Pub MED

Increased risk of overactive bladder in patients with idiopathic Parkinson's disease: Insight from a nationwide population-based cohort study.NUEVO

Lin FY, Yang YC, Lin CL, Lee LJ.
PLoS One. 2018 Mar 2;13(3):e0193783. doi: 10.1371/journal.pone.0193783. eCollection 2018.
Pub MED

Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson's disease.NUEVO

Takahashi H, Watanabe Y, Tanaka H, Mihara M, Mochizuki H, Liu T, Wang Y, Tomiyama N.
Br J Radiol. 2018 Mar 2:20180037. doi: 10.1259/bjr.20180037. [Epub ahead of print]
Pub MED

Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson's Disease.NUEVO

Niranjan R, Mishra KP, Thakur AK.
Mol Neurobiol. 2018 Mar 1. doi: 10.1007/s12035-018-0950-y. [Epub ahead of print]
Pub MED

ER-mitochondria signaling in Parkinson's disease.NUEVO

Gómez-Suaga P, Bravo-San Pedro JM, González-Polo RA, Fuentes JM, Niso-Santano M.
Cell Death Dis. 2018 Mar 1;9(3):337. doi: 10.1038/s41419-017-0079-3. Review.
Pub MED

Quantitative Analysis of Catecholamines in the Pink1 -/- Rat Model of Early-onset Parkinson's Disease.NUEVO

Kelm-Nelson CA, Trevino MA, Ciucci MR.
Neuroscience. 2018 Feb 27;379:126-141. doi: 10.1016/j.neuroscience.2018.02.027. [Epub ahead of print]
Pub MED

Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease.NUEVO

Pretorius E, Page MJ, Mbotwe S, Kell DB.
PLoS One. 2018 Mar 1;13(3):e0192121. doi: 10.1371/journal.pone.0192121. eCollection 2018.
Viendo del 1 al 40 de 753 artículos
Con el aval de:

Sociedad Española de Neurología

Sociedad Española
de Neurología
En colaboración con:

Zambon

Haga click en el logo para acceder
a información acerca de Zambon
NeuroAcademy
Utilizamos cookies propias y de terceros para identificar la sesión del usuario y mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Si continúa navegando por el sitio web manifiesta consentir su instalación y uso conforme lo anterior. Puede cambiar la configuración y obtener más información aquí.